莫西沙星与阿奇霉素治疗急性下呼吸道感染的疗效观察

目的评价莫西沙星与阿奇霉素治疗急性下呼吸道感染的有效性和安全性。方法观察病例数100例。随机分为两组。治疗组：50例。口服莫西沙星片400mg,每天1次;对照组50例,口服阿奇霉素分散片250mg,每天1次,两组疗程均为3～5d。结果莫西沙星和阿奇霉素治疗急性下呼吸道感染的有效率分别为92％和90％。细菌清除率分别为94．7％和93．2％,不良反应发生率分别为4％和6％,两组比较差异均无显著性。结论莫西沙星是治疗急性下呼吸道感染的有效药物,安全性与阿奇霉素相似。     

盐酸莫西沙星治疗下呼吸道感染44例临床分析

目的评价盐酸莫西沙星治疗下呼吸道感染的疗效。方法88例下呼吸道感染患者随机分为两组,治疗组用盐酸莫西沙星注射液0．4g／次,qd;对照组用左氧氟沙星治疗。疗程均为7～10d。结果莫西沙星组和左氧氟沙星组临床总有效率分别为93．2％和90．9％,细菌清除率为94．7％和89．5％,两组小良反应少见而轻微。结论盐酸莫西沙星治疗下呼吸道感染疗效确切,可作为治疗下呼吸道感染的一线用药。     

盐酸莫西沙星在老年肺部或肠道感染中的疗效

目的 考察盐酸莫西沙星对老年肺部或肠道感染的治疗作用及对肾脏的不良反应。方法 盐酸莫西沙星治疗老年肺部感染36例，肠道感染31例。给予盐酸莫西沙星0．4g，每天1～2次．观察临床症状、肾功能及细菌学变化，评价该药的临床疗效及不良反应。结果 临床总有效率88.2％，细菌转阴率86．5％，肾功能无改变，患者耐受性好。结论 盐酸莫西沙星用于治疗老年患者肺部、肠道感染疗效确切，无不良反应。     

莫西沙星、左氧氟沙星和环丙沙星治疗下呼吸道感染的疗效及成本-效果分析

目的 探讨莫西沙星、左氧氟沙星和环丙沙星治疗下呼吸道感染的疗效及成本-效果分析.方法 选择下呼吸道感染患者90例,随机分为3组.莫西沙星组32例,予以莫西沙星片0.4g·d-1,单次口服;左氧氟沙星组30例,予以左氧氟沙星片0.4g·d-1,分2次口服.环丙沙星组28例,予以环丙沙星片1.0g·d-1,分2次口服.3组疗程均为7d.结果 莫西沙星、左氧氟沙星和环丙沙星治疗下呼吸道感染临床有效率分别为90.63％、86.67％和82.14％,细菌清除率分别为84.38％、76.67％和75.0％.3组患者比较均无明显统计学差异(P＞0.05).莫西沙星组的治疗方案成本和成本-效果比分别为202.09元和2.33,左氧氟沙星组分别为15.12元和0.17,环丙沙星组分别为3.64和0.04.环丙沙星组的成本和成本-效果比明显低于莫西沙星组和左氧氟沙星组(P＜0.01).结论 从药物经济学角度分析,环丙沙星组治疗下呼吸道感染的治疗方案较莫西沙星组和左氧氟沙星组为佳.     

莫西沙星治疗老年人下呼吸道感染40例

目的 观察莫西沙星（拜复乐）片剂治疗老年人下呼吸道感染的疗效及安全性。方法莫西沙星400mg口服,每日1次,5-7天为1个疗程。结果 临床总有效率95％,细菌清除率83％,不良反应发生率为5％。结论 口服莫西沙星治疗老年人呼吸道感染安全有效。     

莫西沙星治疗下呼吸道感染的临床观察

目的：观察莫西沙星对下呼吸道感染的疗效与不良反应。方法：采用我院2008年6月～2009年3月住院下呼吸道感染患者84例,随机分成两组,莫西沙星组静脉滴注莫西沙星0．4g,qd,7-14d为1个疗程;左氧沙星组静脉滴注甲磺酸左氧沙星0．4g,qd,7-14d为1个疗程。结果：莫西沙星组总有效率为92％,左氧沙星组有效率76．7％,二者疗效差异有统计学意义（P〈0．05）。结论：莫西沙星治疗下呼吸道感染较左氧沙星更有效。     

莫西沙星治疗呼吸系统感染的安全性与有效性的病例对照分析

目的观察莫西沙星治疗呼吸系统感染的安全性与有效性。方法对70例呼吸道感染患者,分为莫西沙星400mg／d的治疗组和左氧氟沙星300mg／d的对照组,疗程5—10d后进行治疗前后两组间的比较。结果治疗组与对照组的临床总有效率分别为93．3％和92．5％,经统计学处理差异无显著性;不良反应发生率治疗组和对照组分别为6．6％和6．1％,无统计学意义;但3d症状缓解率差异有统计学意义,且总疗程治疗组较对照组缩短。结论莫西沙星治疗呼吸道感染疗效好,副作用较少,不良反应较少,是治疗轻、中、重度呼吸系统感染较理想的药物。     

莫西沙星治疗老年人中-重度下呼吸道感染35例分析

目的评价莫西沙星治疗老年人中．重度下呼吸道感染的临床应用价值。方法采用回顾性研究,将中一重度下呼吸道感染患者57例随机分为两组：治疗组35例,给予莫西沙星注射液0．4g静脉滴注,每日1次;对照组22例,给予左氧氟沙星注射液0。4g静脉滴注,每日1次。疗程均为7～14d。结果治疗组临床治愈率为74．3％,有效率为88．6％,而对照组分别为59．1％,77．3％（P〈0．05）。两组不良反应发生率分别为11。4％和13．6％（P〉0．05）。结论莫西沙星可作为治疗老年人中-重度下呼吸道感染首选用药。     

莫西沙星序贯疗法治疗下呼吸道感染临床观察

目的观察莫西沙星(拜复乐)序贯治疗下呼吸道感染的疗效。方法56例下呼吸道感染患者随机分为2组,治疗组给予静脉点滴莫西沙星(0.4g/250ml),1瓶每日1次,治疗5~7天后,予口服莫西沙星(400mg/片),1片每日1次,治疗3~5天。对照组给予静脉点滴头孢他定(0.2g/支),1支每日2次,治疗7~10天。观察临床指标、细菌学、临床疗效及安全性。结果治疗组与对照组的有效率分别中92.8%、89.3%,细菌清除率分别为88.2%、84.4%,两者比较无显著性差异(P>0.05)。结论莫西沙星在治疗下呼吸道感染中具有良好的临床应用前景。     

盐酸莫西沙星注射液与盐酸莫西沙星氯化钠注射液不良反应对比分析

目的：研究比较盐酸莫西沙星注射液与盐酸莫西沙星氯化钠注射液不良反应发生情况差异。方法选取本院门诊收治2014年04月～2014年09月收治并需选用莫西沙星治疗的患者600例,随机分为观察组与对照组,对照组采用盐酸莫西沙星氯化钠注射液治疗,观察组采用盐酸莫西沙星注射液进行治疗,比较两组不良反应发生情况。结果两组药品不良反应均常见发生率（1％～10％）,其差异不明显（ P＞0．05）。结论国产仿制药盐酸莫西沙星注射液与原研药不良反应没有差异,临床可以选择使用。     

莫西沙星注射液治疗呼吸道细菌性感染的临床研究

目的观察莫西沙星注射液治疗呼吸道细菌性感染的临床疗效与安全性。方法将60例呼吸道细菌性感染患者随机分为治疗组和对照组各30例。治疗组给予莫西沙星注射液静脉滴注;对照组给予左氧氟沙星注射液静脉滴注,疗程均为7～14d。结果治疗组临床总有效率为93.3%,高于对照组的76.7%;细菌清除率为92.0%,高于对照组的80.8%,差异均有统计学意义(P<0.05)。治疗组和对照组不良反应发生率分别为13.3%、16.7%,差异无统计学意义(P>0.05)。结论莫西沙星注射液治疗呼吸道细菌性感染疗效显著,值得临床推广应用。     

Moxifloxacin--a new fluoroquinolone antibacterial

Moxifloxacin (Avelox - Bayer plc), the latest fluoroquinolone antibacterial to be launched in the UK, is licensed for the oral treatment of adults with community-acquired pneumonia, acute exacerbation of chronic bronchitis or acute sinusitis. The company claims that the drug provides "rapid relief from chest infections". Here we review the place of moxifloxacin in treating patients with respiratory tract infections.     

盐酸左氧氟沙星治疗呼吸系统细菌感染的临床比较研究

目的观察盐酸左氧氟沙星对呼吸系统细菌感染效果。方法选取呼吸系统细菌感染患者150例,分为左氧氟沙星组和环丙沙星组,分别静点左氧氟沙星和环丙沙星,比较两组患者的症状缓解时间和细菌清除率。结果左氧氟沙星组的细菌清除率为90.27%,症状缓解时间为(3.5±1.2)d,环丙沙星组的细菌清除率为73.97%,症状缓解时间为(6.8±1.4)d,统计学分析,P<0.05,有统计学意义。结论盐酸左氧氟沙星治疗呼吸系统细菌感染起效快、细菌清除率高。     

甲磺酸加替沙星注射液治疗急性尿路感染的疗效观察

目的探讨甲磺酸加替沙星注射液治疗急性尿路感染的有效性和安全性。方法将临床确诊为急性尿路感染的患者126例随机分为试验组和对照组,各63例,试验组给予甲磺酸加替沙星注射液（Gatifloxacin Mesylate Injection）400mg,静脉滴注,每日1次;对照组给予盐酸左氧氟沙星注射液（Levofloxacin Hydrochloride Injection）200mg,静脉滴注,每日2次,疗程7～14d。结果甲磺酸加替沙星组与盐酸左氧氟沙星组痊愈率分别为79．36％与68．25％;有效率分别为92．06％与80．95％;细菌清除率分别为93．65％与82．54％。两组比较,P〉0．05。不良反应发生率分别为3．17％与4．76％,不良反应较轻。随访复发率试验组低于对照组,P〈0．05。结论甲磺酸加替沙星注射液治疗急性尿路感染与盐酸左氧氟沙星注射液效果相当,不良反应较少,耐受性好。     

Moxifloxacin: a review of its clinical potential in the management of community-acquired respiratory tract infections

Moxifloxacin is an extended-spectrum fluoroquinolone which has improved coverage against gram-positive cocci and atypical pathogens compared with older fluoroquinolone agents, while retaining good activity against gram-negative bacteria. The antibacterial spectrum of moxifloxacin includes all major upper and lower respiratory tract pathogens; it is one of the most active fluoroquinolones against pneumococci, including penicillin- and macrolide-resistant strains. In in vitro studies, emergence of bacterial resistance was less common with moxifloxacin than with some other fluoroquinolones, but this requires confirmation in large-scale clinical studies. As with other fluoroquinolones, moxifloxacin achieves good penetration into respiratory tissues and fluids. It shows a low potential for drug interactions and dosage adjustment is not required for patients of advanced age or those with renal or mild hepatic impairment. The efficacy of oral moxifloxacin has been demonstrated in large, well-designed clinical trials in patients with community-acquired pneumonia, acute exacerbations of chronic bronchitis or acute sinusitis. Moxifloxacin 400 mg once daily achieved bacteriological and clinical success rates of approximately 90% or higher. It was as effective as, or more effective than, comparators including clarithromycin, cefuroxime axetil and high dose amoxicillin in these trials. The most commonly reported adverse events in patients receiving moxifloxacin are gastrointestinal disturbances. Moxifloxacin is also associated with QTc prolongation in some patients; there are, as yet, no data concerning the possible clinical sequelae of this effect in high-risk patients. Moxifloxacin has a low propensity for causing phototoxic reactions relative to other fluoroquinolones, and animal data suggest that it has a low potential for causing excitatory CNS and hepatotoxic effects. Conclusions: As an extended-spectrum fluoroquinolone, moxifloxacin offers the benefits of excellent activity against pneumococci, once daily administration and a low propensity for drug interactions. Although studies are needed regarding its tolerability in at-risk patients with QT interval prolongation, available data suggest that moxifloxacin is likely to become a first-line therapy option for the treatment of community-acquired lower respiratory tract infections, particularly in areas where drug-resistant S. pneumoniae or H. influenzae are common.     

Moxifloxacin: new preparation. A me-too with more cardiac risks

(1) Moxifloxacin is the fourth fluoroquinolone to be licensed in France with indications covering ENT and respiratory tract infections. (2) In community-acquired pneumonia, acute bacterial sinusitis and acute exacerbations of chronic bronchitis, moxifloxacin seems no more effective than other fluoroquinolones available in France (with which it has not been compared) or the other antibiotics with which it has been compared. (3) Moxifloxacin has the usual adverse effects of fluoroquinolones, but carries a greater risk of QT prolongation than ciprofloxacin, levofloxacin and ofloxacin.     

盐酸莫西沙星搽剂的制备及质量控制

目的制备盐酸莫西沙星搽剂并建立其质量控制方法。方法以盐酸莫西沙星为主药制备搽剂;采用高效液相色谱法测定其中主药含量,并考察其稳定性。结果盐酸莫西沙星检测浓度的线性范围为6.0～36μg.mL-1(r=0.999 9),平均回收率为99.81%(RSD=0.506%,n=9)。结论本制剂制备工艺简便可行,质量稳定可控。     

Clinical studies on cefoxitin in the treatment of respiratory tract infections

The clinical effects of cefoxitin (CFX) were studied in 31 cases of respiratory tract infections. The results were as follows: As for the clinical effects, CFX was excellent in 5 cases, good in 13, fair in 8 and poor in 5 out of 31 patients; the efficacy rate was 58.1%. The efficacy rate was 57.1% in bronchopneumonia, 61.1% in pneumonia and 50.0% in acute exacerbation of chronic respiratory tract infections. The efficacy rate was 70.6% in the group of 4 g/day or less and 42.9% in the group of 6 g/day or more. The efficacy rate was 50.0% in 6 cases that had not been responded to other antibiotics previously. As for side effects, skin eruption was observed in only 1 patient. No abnormality was observed in laboratory tests due to CFX. In conclusion, CFX is a useful drug in the treatment of respiratory tract infections.     

克拉霉素片治疗急性细菌性上呼吸道感染的临床观察

目的：分析克拉霉素治疗急性细菌性上呼吸道感染的有效性和安全性．方法：采用随机对照实验将70例上呼吸道感染病人分为两组,观察其临床疗效和不良反应,其中36例用克拉霉素,34例用乙琥红霉素,连用5～7d．克拉霉素的用法,250mg,po,tid．琥乙红霉素的用法,500mg,po,tid。结果：两组临床痊愈率和有效率分别为66．7％、94．4％和44．1％、76．5％细菌清除率分别为96．2％和90．9％不良反应发生率分别为5．6％和3．5％。结论：新一代大环内酯类抗生素克拉菌素片为治疗急性上呼吸道感染安全有效的药物。